Programmed cell death-1 ligand (PD-L1) expression on circulating CD45(-) cells is an independent prognostic factor for overall survival in patients (Pts) with lung cancer in a prospective, multicenter cohort.

Daniel J. Boffa, Jorge J. Nieva, Lyudmila Bazhenova, Rachel Krupa, David Lu, Ryon P. Graf, Jessica Louw, Lyndsey Dugan, Adam Jendrisak, Michelle C. Salazar, Samir Makani, Marisa Magaña, Sarah Orr, Kelly Bethel, Yipeng Wang, Dena Marrinucci, Ryan Dittamore, EpicJournal of Clinical Oncology 2016 · DOI

Abstract

8524 Background: Lung cancer pts currently require biopsies to diagnose and profile tumors prior to treatment. There is a need for tumor profiling from circulating biomarkers to avoid invasive procedures. PD-L1 expression on lung cancer biopsy specimens correlates with efficacy of immune checkpoint therapy. However, the expression of PD-L1 on circulating cells has not been fully characterized, limiting their ability to guide therapy. Using the Epic Sciences PD-L1 assay, we sought to correlate patient outcome with PD-L1(+) circulating CD45(-) cells, as a prerequisite to prospective evaluation as a predictive biomarker. Methods: Peripheral blood was collected from pts at three clinical sites prior to diagnostic biopsy (baseline), or at follow-up. 100 lung cancer pts with diverse histology were selected for interim analysis. All nucleated cells were plated onto glass slides and circulating cells of interest identified by immunofluorescence and morphological features. Prognostic capacity of PD-L1(+) cells (CK+/-, CD45-, PD-L1+, malignant nuclear morphology) were assessed with Kaplan-Meier and Cox Proportional Hazard (PH) models. Results: (See Table.) PD-L1 localization was primarily membranous in (+) cells. Pts with >1 PD-L1(+) cell/mL in baseline samples had worse overall survival (OS) (n=16/100, mOS: 16.1 months vs. not reached, HR = 3.46, p = 0.0022) and follow-up (n=4/16 mOS = 0.6 months vs. not reached, HR = 9.62, p < 0.0001). Adjusting for AJCC staging, high PD-L1(+) cell burden remained significant in multivariate models at both baseline (HR = 2.41, p = 0.0492) and follow-up (HR = 11.5, p = 0.0407). Single-cell sequencing is underway to further assess malignant origin of PD-L1(+) cells. Conclusions: In a prospectively enrolled, multicenter cohort, PD-L1(+) cell burden prognosticated OS in univariate and multivariate settings, independent to AJCC staging in pre-biopsy and follow-up samples. This lays the groundwork for PD-L1(+) CTCs to be prospectively assessed as a predictive biomarker to immune checkpoint inhibitors in lung cancer. AJCC Stage n = 100 Baseline n = 16 Follow-Up I 40 2 II 16 2 III 25 5 IV 19 7
BibTeX
@article{boffa2016programmed,
  author = {Daniel J. Boffa and Jorge J. Nieva and Lyudmila Bazhenova and Rachel Krupa and David Lu and Ryon P. Graf and Jessica Louw and Lyndsey Dugan and Adam Jendrisak and Michelle C. Salazar and Samir Makani and Marisa Magaña and Sarah Orr and Kelly Bethel and Yipeng Wang and Dena Marrinucci and Ryan Dittamore and EPIC},
  title = {{Programmed cell death-1 ligand (PD-L1) expression on circulating CD45(-) cells is an independent prognostic factor for overall survival in patients (Pts) with lung cancer in a prospective, multicenter cohort.}},
  journal = {Journal of Clinical Oncology},
  year = {2016},
  doi = {10.1200/jco.2016.34.15\_suppl.8524},
}

Loading related content...

Figure